Guggenheim Initiates Coverage on Sensei Biotherapeutics (NASDAQ:FTH)

Investment analysts at Guggenheim assumed coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research note issued on Wednesday, Benzinga reports. The brokerage set a “buy” rating and a $70.00 price target on the stock. Guggenheim’s target price indicates a potential upside of 97.91% from the stock’s previous close.

Several other research firms have also recently weighed in on FTH. Wall Street Zen upgraded Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Oppenheimer initiated coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price objective for the company. Loop Capital set a $50.00 price target on Sensei Biotherapeutics in a research note on Thursday, May 28th. Needham & Company LLC started coverage on Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a “buy” rating and a $56.00 price objective for the company. Finally, Raymond James Financial started coverage on Sensei Biotherapeutics in a report on Friday, July 31st. They set an “outperform” rating and a $56.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Sensei Biotherapeutics has an average rating of “Moderate Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Trading Down 9.5%

Shares of FTH stock opened at $35.37 on Wednesday. The company has a market capitalization of $913.96 million, a PE ratio of -0.25 and a beta of -0.28. Sensei Biotherapeutics has a 1 year low of $7.45 and a 1 year high of $42.14. The company has a 50 day moving average of $31.81.

Sensei Biotherapeutics (NASDAQ:FTH) last released its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. On average, equities research analysts predict that Sensei Biotherapeutics will post -13.69 earnings per share for the current fiscal year.

Insider Transactions at Sensei Biotherapeutics

In related news, CFO Brian C. Stephenson purchased 9,391 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were bought at an average price of $26.13 per share, with a total value of $245,386.83. Following the acquisition, the chief financial officer owned 26,804 shares of the company’s stock, valued at $700,388.52. This trade represents a 53.93% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Anand Kiran Parikh acquired 2,806 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. The trade was a 0.37% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 49,494 shares of company stock worth $1,188,822. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

Several hedge funds have recently made changes to their positions in FTH. Vivo Capital LLC bought a new position in shares of Sensei Biotherapeutics during the 1st quarter worth $22,758,000. Alyeska Investment Group L.P. purchased a new stake in Sensei Biotherapeutics during the second quarter valued at about $3,610,000. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics in the first quarter worth about $4,188,000. Bank of America Corp DE raised its position in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares in the last quarter. 10.50% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.